MLchartDataset catalogue

Dolutegravir

Term · Oncology and biomedicine · MLC-T-ONC-013132

An orally bioavailable integrase strand transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication.

Table 1. Record
IdentifierMLC-T-ONC-013132
FieldOncology and biomedicine
AbbreviationDTG
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013132",
  "term": "Dolutegravir",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable integrase strand transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication.",
  "abbreviation": "DTG",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dolutegravir/"
}

Record 6,161 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.